Anti-Inflammatory Biologics Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Anti-Inflammatory Biologics Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for anti-inflammatory biologics has experienced substantial expansion in recent years. Projections indicate it will increase from $118.02 billion in 2025 to $128.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth has been driven by factors such as the constrained availability of biologics, dependence on conventional anti-inflammatory medications, a rising incidence of rheumatoid arthritis and psoriasis, the development of hospital and clinic facilities, and growing financial commitments to immunology research.
The anti-inflammatory biologics market is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $180.93 billion, driven by a compound annual growth rate (CAGR) of 8.9%. This forecasted growth is fueled by the emergence of next-generation cytokine inhibitors, broader availability of home care and self-administration options, an uptick in regulatory approvals alongside expedited clinical trial timelines, heightened investment in precision medicine and biologics research, and expanding collaborations between pharmaceutical and biotechnology firms. Key trends shaping this period include a growing preference for targeted biologics addressing chronic inflammatory conditions, advancements in subcutaneous and injectable drug delivery methods, an increase in clinical trials and research into novel anti-inflammatory biologics, a stronger emphasis on tailored treatment approaches, and greater awareness and accessibility of biologics within emerging markets.
Download A Free Sample Report For Comprehensive Market Insights:
Anti-Inflammatory Biologics Market Demand Drivers: What Is Fueling Industry Growth?
The upward trend in arthritis cases is anticipated to fuel the expansion of the anti-inflammatory biologics market in the coming period. Arthritis is characterized by joint inflammation or swelling, which results in pain, stiffness, and diminished mobility, and these symptoms tend to intensify with advancing age. This increase in arthritis prevalence is largely attributable to climbing obesity rates, as surplus body weight imposes increased pressure on joints, thereby triggering inflammation and joint deterioration. Anti-inflammatory biologics prove beneficial for managing arthritis by zeroing in on particular immune system elements to curb inflammation, decelerate joint deterioration, alleviate symptoms, and enhance both physical function and overall quality of life for individuals suffering from moderate to severe arthritis. As an example, data from the Office for Health Improvement and Disparities, a UK government body, indicates that in January 2024, 18.4% of people aged 16 and over in 2023 reported a long-term musculoskeletal condition, an increase from 17.6% in 2022. Consequently, the growing occurrence of arthritis is propelling the advancement of the anti-inflammatory biologics market.
Anti-Inflammatory Biologics Market Segment Analysis And Revenue Opportunities
The anti-inflammatory biologics market covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics
Anti-Inflammatory Biologics Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading firms in the anti-inflammatory biologics sector are concentrating on creating innovative products, including interleukin-6 (IL-6) receptor antagonists, to treat chronic inflammatory diseases with enhanced precision and minimized adverse effects. These biologic drugs work by blocking the IL-6 receptor, thereby dampening inflammation and immune activity in disorders like rheumatoid arthritis. A notable example occurred in February 2023, when Regeneron Pharmaceuticals Inc., a biotechnology company based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for Kevzara. This approval marked it as the first and only biologic therapy indicated for patients with polymyalgia rheumatica (PMR) who have an inadequate response to corticosteroids. Kevzara, a fully human monoclonal antibody, functions by inhibiting the IL-6 receptor, which alleviates inflammation associated with PMR—a condition characterized by muscle pain and stiffness, typically affecting older individuals. In contrast to conventional steroids, which pose risks like osteoporosis and diabetes when used over extended periods, Kevzara offers a more targeted, steroid-sparing therapeutic option that promotes better patient outcomes and improved long-term safety.
Anti-Inflammatory Biologics Market Leading Players Shaping Industry Direction
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A
Access The Complete Anti-Inflammatory Biologics Market Report:
Anti-Inflammatory Biologics Market Regional Analysis And Leading Geography
North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
